January 25, 2024
(press release)
–
Essen, Germany. Evonik’s strides to bolster the supply of amino acids for animal feed in the Americas will take center stage at the upcoming International Production & Processing Expo (IPPE), in Atlanta, Georgia, USA, occurring from January 30th to February 1st. Evonik’s focus at the event includes highlighting its fully integrated methionine production in Mobile, Alabama – to be completed in Q3, 2024 – which is designed to strengthen regional supply security and deliver significant sustainability gains. After completion of the backward integration, Evonik will save 25,000 metric tons of CO2 emissions annually at its Mobile methionine plant. Gaetano Blanda, head of the Animal Nutrition business line, said: “Security of supply is a top priority for the industry, which is why this is our focus at IPPE. The investment in our methionine plant in Mobile will enable us to become more independent from volatile global supply chains and further strengthen the service we provide to our customers in the Americas region.” At the booth, attendees will be able to pick up the second edition of the new MetAMINO® ATLAS, containing the most up-to-date academic research and field trials in the use of MetAMINO® in animal nutrition. There will also be live demonstrations of Evonik’s AMINONIR® analytical services and detailed insights on AMINOSys® handling solutions. These will show the benefits of determining the real nutritional profile of feed and fully automated dosing – from more informed purchasing decisions to better animal productivity and performance. In addition, Evonik’s feed ingredient database AMINODat® 6.2 has been updated ahead of the event with fresh crop data from the US, including state-specific data for corn and soybean meal. The team will be on hand to discuss how Evonik is “Sciencing the Global Food Challenge”, including its increased focus on probiotics, as part of its commitment to helping the industry reduce reliance on antibiotics as growth promoters (AGPs). GutCare®, Ecobiol® and Ecobiol Fizz® all form part of Evonik’s Gut Health Solutions for swine and poultry. During the trade show, Fernanda Castro, Evonik’s Technical Service Manager and Global Sustainability Coordinator for the inoSust® program, will present a TECHTalk on the “Application of advanced nutritional concepts and technologies to improve the sustainability of poultry production”. The session, in Hall A, Booth A244, will take place at 11:00 EST on Wednesday, January 31. The Evonik booth is located in Hall A, Booth A1533. Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow. The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees. In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
